failing, page-31

re: failing and the alternative. Probably the case dynofish although $1 capital raising in my opinion would be too low. Given the last was at $2.25 and with no human trial history you would have though the next cap. raising would be closer to this price than $1. However, given the SP has averaged around $1.30-$1.40 over the last 2 years I'm guessing it will be around these levels or just under.

How much cash do they need is the other question. Given that they are receiving reimbursement from the US trials and should be selling into Europe next year, I think anywhere between $20-30 million. They had just over $30 million as at the end of June 30. Given they burn $2-2.5 mill a month this would mean enough cash for 2 more years. Enough to see them through the US trials.

This would bring there total number of shares to around 215 million. Dilution is not a real big issue IMO.

Watch patdone, syringe and others come out with objections and rubbish. Good luck